Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 8/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | MEP1A | Q16819 | 1/20 | 0.31 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3310091 | 0.82 | GPR84 (0.31) | GPR84 | |
| SCHEMBL3648503 | 0.82 | RIPK1 (0.34) | CES2CES1RIPK1GPR84CA2 | |
| SCHEMBL31167589 | 0.82 | MEP1A (0.32) | GPR84MEP1AMEP1B | |
| SCHEMBL5156289 | 0.80 | P2RX7 (0.32) | RIPK1GPR84P2RX7 | |
| SCHEMBL2179956 | 0.80 | P2RX7 (0.35) | RIPK1P2RX7 | |
| SCHEMBL16041142 | 0.80 | — | — | |
| SCHEMBL15312004 | 0.80 | RIPK1 (0.33) | RIPK1 | |
| SCHEMBL127091 | 0.79 | TAAR1 (0.39) | CES2CES1RIPK1GPR84MEP1B | |
| SCHEMBL5734027 | 0.79 | TAAR1 (0.39) | CES2CES1RIPK1GPR84MEP1B | |
| SCHEMBL81560 | 0.79 | SIRT2 (0.34) | CES2CES1RIPK1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 249 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115745766-B | Preparation method of trifluorobenzaldehyde and trifluorobenzyl bromide | 兰州康鹏威耳化工有限公司 | 2024-05-14 | — | — | CN | claimed |
| CN-115745766-A | Preparation method of trifluorobenzaldehyde and trifluorobenzyl bromide | 兰州康鹏威耳化工有限公司 | 2023-03-07 | — | — | CN | claimed |
| CN-114853560-A | Preparation method of 2,4, 5-trifluorobenzyl bromide and 2,4, 5-trifluorobenzoic acid | 湖南复瑞生物医药技术有限责任公司 | 2022-08-05 | — | — | CN | claimed |
| US-12570642-B2 | GLP-IR modulating compounds | GILEAD SCIENCES, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4691554-A2 | GLP-1R MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4271672-B1 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20250122171-A1 | Substituted Amine Compounds, Compositions and Methods of Use | DEEP APPLE THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| WO-2025064534-A1 | SUBSTITUTED AMINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | DEEP APPLE THERAPEUTICS, INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| EP-3689879-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2025-02-12 | — | — | EP | disclosed |
| EP-4219463-B1 | TERPYRIDINE DIKETONE COMPOUND OR SALT THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHENZHEN SALUBRIS PHARM CO LTD (CN) | 2025-01-15 | — | — | EP | disclosed |
| EP-3224237-B1 | NECROSIS INHIBITORS | NAT INSTITUTE OF BIOLOGICAL SCIENCES BEIJING (CN) | 2024-09-11 | — | — | EP | disclosed |
| WO-2000024719-A1 | PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2000-05-04 | — | — | WO | disclosed |
| WO-1999015178-A1 | VITRONECTIN RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-01 | — | — | WO | disclosed |
| EP-0640595-B1 | SUBSTITUTED TERTIARY AMINO COMPOUND OR SALT THEREOF | YAMANOUCHI PHARMA CO LTD (JP) | 1999-03-24 | — | — | EP | disclosed |
| WO-1999010331-A1 | ARYLPYRIDAZINONES AS PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LABORATORIES (US) | 1999-03-04 | — | — | WO | disclosed |
| CN-1039228-C | Novel substituted tert-amino compund | YAMANOUCHI PHARMA CO LTD (JP) | 1998-07-22 | — | — | CN | disclosed |
| US-5651919-A | Benzyl ether derivative and composition containing the same | CITIZEN WATCH CO., LTD. (JP) | 1997-07-29 | — | — | US | disclosed |
| US-5538976-A | ANTICARCINOGENIC AGENTS AND ENZYME INHIBITORS FOR AROMATASE | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1996-07-23 | — | — | US | disclosed |
| EP-0640595-A1 | NOVEL SUBSTITUTED TERTIARY AMINO COMPOUND OR SALT THEREOF | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1995-03-01 | — | — | EP | disclosed |
| CN-1079962-A | New substituted tertiary amine compound and salt thereof | YAMANOUCHI PHARMA CO LTD (JP) | 1993-12-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122171-A1 | Substituted Amine Compounds, Compositions and Methods of Use | MRGPRX2, MRGPRX1, MRGPRX4 | CES2 158/4885CES1 843/4885RIPK1 4804/4885 |
| US-12570642-B2 | GLP-IR modulating compounds | GLP1R, GIPR, GPR119 | CES2 2669/4885CES1 673/4885RIPK1 1917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.